Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks
Egeberg, Alexander (University of Copenhagen)
Kristensen, Lars E. (University of Copenhagen & Bispebjerg University Hospital (Dinamarca))
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Rich, Phoebe (Oregon Dermatology and Research Center (Estats Units d'Amèrica))
Smith, Saxon (The Australian National University (Austràlia))
Garrelts, Alyssa (Eli Lilly and Company (Indiana, Estats Units d'Amèrica))
See, Kyoungah (Eli Lilly and Company (Indiana, Estats Units d'Amèrica))
Holzkaemper, Thorsten (Eli Lilly and Company (Indiana, Estats Units d'Amèrica))
Fotiou, Konstantinos (Eli Lilly and Company (Indiana, Estats Units d'Amèrica))
Schuster, Christopher (Medical University of Vienna)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	Available network meta-analyses (NMAs) comparing the efficacy of biologics in nail psoriasis (NP) have not included recently approved biologics such as bimekizumab nor have they provided comparisons up to 1 year. Objective: We conducted two NMAs that update and extend results from a previous NMA comparing biologics for achieving complete resolution of NP. Bayesian NMAs were performed using a generalized linear model with a logit link to model the binary outcome of nail clearance at weeks 24-28 and 48-52. For the NMA at weeks 24-28, which included seven biologics and placebo, the absolute probability of achieving complete resolution of NP was highest for ixekizumab (46. 4%; 95% credibility interval [CrI] 35. 2-58. 0), followed by brodalumab (37. 1%; 95% CrI 17. 1-62. 2) and bimekizumab (30. 3%; 95% CrI 12. 7-53. 9). For the NMA at weeks 48-52, which included six biologics, the absolute probability was highest for ixekizumab (77. 2%; 95% CrI 51. 1-93. 4), followed by adalimumab (75. 6%; 95% CrI 61. 5-87. 3) and brodalumab (71. 9%; 95% CrI 38. 4-93. 2). Among biologics included in these two NMAs, ixekizumab has the highest absolute probability of achieving complete resolution of NP. Results may help to inform treatment decisions for patients with NP.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Nail Psoriasis Severity Index (NAPSI) ; Nail psoriasis ; Physician's Global Assessment of Fingernails (PGA-F) ; Biologics ; Complete clearance/resolution of nail psoriasis ; Ixekizumab ; Network meta-analysis
Publicat a:	Journal of Dermatological Treatment, Vol. 34 Núm. 1 (2023) , p. 2263108, ISSN 1471-1753

DOI: 10.1080/09546634.2023.2263108
PMID: 37781881

6 p, 1.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats